News & Updates

ACOG article 2.3

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Gatekeeping model central to primary care across region

The gatekeeping model was a common theme among the presentations of Datin Dr. Noraslinah of the Ministry of Health in Brunei Darussalam, Dr. Zorayda Leopando of the Department of Family and Community Medicine at the University of the Philippines College of Medicine and Dr. Somjit Prueksaritanond of the Royal College of Family Physicians of Thailand regarding their respective countries’ experiences at implementing primary care during the conference.

Revisions in the International Standards for Tuberculosis Care 2014

The International Standards for Tuberculosis Care (ISTC), 3rd edition, (The Hague, 2014) is a set of recommendations made by a global coalition of organizations, including the WHO, and financed by the US Agency for International Development (USAID).  It aims to facilitate the commitment of all care providers in delivering high-quality care for patients of all ages. “It is intended to complement, not replace national and local recommendations”, both Dr. Jubert Benedicto, past National Chair of Philippine Coalition Against Tuberculosis (PHILCAT), and Dr. Rontgene Solante, Board Secretary of PHILCAT, emphasized during their talks at the recent PhilCAT convention.

Higher aspirin dose may attenuate severe pre-eclampsia risk among high-risk women with obesity

Doubling the routine aspirin dose used for pre-eclampsia prevention appears to help lower the risk of developing pre-eclampsia with severe features among high-risk pregnant women with obesity, according to the results of the open-label ASPREO trial.

Family-oriented primary care underappreciated in Vietnam

Maternal transplacental transfer of nipocalimab negligible in foetuses, neonates

In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.